Health

Genmab Provides Certain Information Disclosed in Connection with Proposed Private Offering of Senior Secured Notes and Senior Unsecured Notes

Media Release COPENHAGEN, Denmark; November 10, 2025 Genmab A/S (“Genmab”) announced on November 10, 2025, that it and its wholly…

4 months ago

AHA 2025: Late-Breaking Data Reinforce the Prognostic Power of AI-Driven Heartflow Plaque Analysis as the Most Clinically Validated Framework for Coronary Risk Stratification

Multicenter outcomes FISH&CHIPS study of nearly 8,000 patients confirms total plaque volume as a powerful independent predictor of long-term cardiovascular…

4 months ago

George Medicines presents long-term efficacy and safety data for single pill triple combination therapy for hypertension at American Heart Associations Scientific Sessions 2025

London, UK, Boston, MA, 9 November 2025 – George Medicines, a late-stage biopharmaceutical company focused on addressing significant unmet needs…

4 months ago

Medera Presents Late-Breaking Data from First-In-Human Gene Therapy Trial for Heart Failure with Preserved Ejection Fraction at American Heart Association Scientific Sessions 2025

November 09, 2025 09:00 ET  | Source: Medera Inc. BOSTON, Nov. 09, 2025 (GLOBE NEWSWIRE) -- Medera Inc. ("Medera"), a…

4 months ago

Intellia Therapeutics Presents Positive Pooled Phase 1/2 Data of Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema

November 08, 2025 17:13 ET  | Source: Intellia Therapeutics, Inc. Deep, stable and durable reductions in kallikrein observed Among 32 patients…

4 months ago

Clinical Data Demonstrating Efficacy of Sotagliflozin in Preserved Ejection Fraction Heart Failure (HFpEF) without Diabetes Presented at American Heart Association (AHA) Annual Scientific Sessions 2025

THE WOODLANDS, Texas, Nov. 08, 2025 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that new sotagliflozin clinical…

4 months ago

Telitacicept Achieved Primary Endpoint of Reducing Proteinuria in Stage A of a Phase 3 Clinical Study for IgA Nephropathy in China

November 08, 2025 11:45 ET  | Source: Vor Biopharma Treatment with telitacicept for 39 weeks resulted in a rapid, clinically…

4 months ago

Smile Spa Camarillo Officially Opens its Doors, Offering State-of-the-Art Dental Care in Ventura County

Camarillo, CA, Nov. 07, 2025 (GLOBE NEWSWIRE) -- Smile Spa Camarillo, a modern dental office led by Dr. Joelle Abed…

4 months ago

Vera Therapeutics Submits Biologics License Application to U.S. FDA through Accelerated Approval Program for Atacicept for the Treatment of Adults with IgA Nephropathy

Atacicept received FDA Breakthrough Therapy Designation for the treatment of IgANORIGIN Phase 3 trial met its primary endpoint at the…

4 months ago

Data for Lorundrostat in Chronic Kidney Disease and Hypertension Presented at American Society of Nephrology (ASN) Kidney Week 2025

– Late-breaking presentation of Explore-CKD trial at ASN Kidney Week – – Pivotal Phase 3 Launch-HTN trial featured in the…

4 months ago